599 related articles for article (PubMed ID: 18554655)
1. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases.
Ishioka J; Kageyama Y; Inoue M; Higashi Y; Kihara K
J Urol; 2008 Aug; 180(2):618-21; discussion 621. PubMed ID: 18554655
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in malignant ureteric obstruction.
Lienert A; Ing A; Mark S
BJU Int; 2009 Oct; 104(7):938-41. PubMed ID: 19338533
[TBL] [Abstract][Full Text] [Related]
3. A prognostic model for survival after palliative urinary diversion for malignant ureteric obstruction: a prospective study of 208 patients.
Cordeiro MD; Coelho RF; Chade DC; Pessoa RR; Chaib MS; Colombo-Júnior JR; Pontes-Júnior J; Guglielmetti GB; Srougi M
BJU Int; 2016 Feb; 117(2):266-71. PubMed ID: 25327474
[TBL] [Abstract][Full Text] [Related]
4. Malignant ureteral obstruction: outcomes after intervention. Have things changed?
Wong LM; Cleeve LK; Milner AD; Pitman AG
J Urol; 2007 Jul; 178(1):178-83; discussion 183. PubMed ID: 17499300
[TBL] [Abstract][Full Text] [Related]
5. The role of percutaneous nephrostomy in malignant ureteric obstruction.
Wilson JR; Urwin GH; Stower MJ
Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
[TBL] [Abstract][Full Text] [Related]
6. Use of nephrostomy tubes in ureteric obstruction from incurable malignancy.
Little B; Ho KJ; Gawley S; Young M
Int J Clin Pract; 2003 Apr; 57(3):180-1. PubMed ID: 12723719
[TBL] [Abstract][Full Text] [Related]
7. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes.
Kouba E; Wallen EM; Pruthi RS
J Urol; 2008 Aug; 180(2):444-50. PubMed ID: 18550089
[TBL] [Abstract][Full Text] [Related]
8. [Relief of upper urinary tract obstruction in patients with cancer of the prostate].
Kraemer PC; Borre M
Ugeskr Laeger; 2009 Mar; 171(11):873-6. PubMed ID: 19278608
[TBL] [Abstract][Full Text] [Related]
9. Palliative Subcutaneous Tunneled Nephrostomy Tube (PSTN): a simple and effective technique for management of malignant extrinsic ureteral obstruction.
Bell DG; Fischer MA
Can J Urol; 2002 Feb; 9(1):1470-4. PubMed ID: 11886602
[TBL] [Abstract][Full Text] [Related]
10. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?
Ku JH; Lee SW; Jeon HG; Kim HH; Oh SJ
Urology; 2004 Nov; 64(5):895-9. PubMed ID: 15533473
[TBL] [Abstract][Full Text] [Related]
11. Management of extrinsic malignant ureteral obstruction with urinary diversion.
Kanou T; Fujiyama C; Nishimura K; Tokuda Y; Uozumi J; Masaki Z
Int J Urol; 2007 Aug; 14(8):689-92. PubMed ID: 17681056
[TBL] [Abstract][Full Text] [Related]
12. Current outcome of patients with ureteral stents for the management of malignant ureteral obstruction.
Izumi K; Mizokami A; Maeda Y; Koh E; Namiki M
J Urol; 2011 Feb; 185(2):556-61. PubMed ID: 21168872
[TBL] [Abstract][Full Text] [Related]
13. Complications of percutaneous nephrostomy in the treatment of malignant ureteral obstructions: single-centre review.
Carrafiello G; Laganà D; Mangini M; Lumia D; Recaldini C; Bacuzzi A; Marconi A; Mira A; Cuffari S; Fugazzola C
Radiol Med; 2006 Jun; 111(4):562-71. PubMed ID: 16779542
[TBL] [Abstract][Full Text] [Related]
14. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model.
Alawneh A; Tuqan W; Innabi A; Al-Nimer Y; Azzouqah O; Rimawi D; Taqash A; Elkhatib M; Klepstad P
J Pain Symptom Manage; 2016 Feb; 51(2):255-61. PubMed ID: 26497918
[TBL] [Abstract][Full Text] [Related]
15. Nephrostomy in patients with ureteral obstruction secondary to nonurologic malignancy. Obstructive uropathy in malignant disease.
McNamara TE; Butkus DE
Arch Intern Med; 1980 Apr; 140(4):494-7. PubMed ID: 7362379
[TBL] [Abstract][Full Text] [Related]
16. Impact of palliative urinary diversion by percutaneous nephrostomy drainage and ureteral stenting among patients with advanced cervical cancer and obstructive uropathy: a prospective cohort.
Lapitan MC; Buckley BS
J Obstet Gynaecol Res; 2011 Aug; 37(8):1061-70. PubMed ID: 21481096
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous nephrostomy and ureteral stenting in gynecologic malignancies.
Barton DP; Morse SS; Fiorica JV; Hoffman MS; Roberts WS; Cavanagh D
Obstet Gynecol; 1992 Nov; 80(5):805-11. PubMed ID: 1407920
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
[TBL] [Abstract][Full Text] [Related]
19. Posterior urethral valves with persistent high serum creatinine: the value of percutaneous nephrostomy.
Ghali AM; El Malki T; Sheir KZ; Ashmallah A; Mohsen T
J Urol; 2000 Oct; 164(4):1340-4. PubMed ID: 10992410
[TBL] [Abstract][Full Text] [Related]
20. The management of malignant ureteral obstruction treated with ureteral stents.
Ganatra AM; Loughlin KR
J Urol; 2005 Dec; 174(6):2125-8. PubMed ID: 16280741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
